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Abstract
The majority of patients who present with hilar cholangiocarcinoma will have incurable disease and require only palliation.
Efficient relief of disabling symptoms is required with minimal morbidity and mortality and can be achieved by either surgical
or non-operative options. A review of the indications, anatomical considerations and surgical techniques is presented.
Segment III cholangio-jejunostomy is the most frequently used surgical bypass procedure and in those patients with an
expected survival of more than 6 months, surgical palliation offers good quality and long-lasting palliation. There is a need for
randomized controlled data to define the optimal role of surgical palliation in this difficult disease.
Introduction
Cholangiocarcinoma is an uncommon malignancy
with an incidence in the UK of 2.3/100 000, which
is increasing [1]. Hilar cholangiocarcinoma accounts
for up to 80% [2] of these tumours and the overall
prognosis is poor with a mean survival of 21 months
[2]. Despite improvements in preoperative imaging,
surgical technique and understanding of the local
patterns of spread, an attempted curative resection
can only be achieved in 36% of patients [3]. Given
that 470% of patients present with jaundice [4,5], a
significant proportion of patients will require palliative
biliary decompression to relieve their symptoms.
Options for palliation consist of either surgical [6–9]
or radiological [6,10,11] procedures and both are
associated with morbidity and mortality [6–8,10,11].
Controversy exists as to which provides superior
palliation [4,6,8] and there are no randomized con-
trolled data to provide guidance. The aim of this review
is to discuss indications for palliation, anatomical
considerations and surgical techniques involved in
palliation of unresectable hilar cholangiocarcinoma
and to determine their current role.
Indications for palliation
Hilar cholangiocarcinoma may be considered un-
resectable because of patient- and tumour-related
factors [3]. Unresectability alone does not necessarily
imply that palliative intervention is required. The aim
of palliation is to optimize the quality and quantity of
remaining life, with minimal morbidity (both early and
late) and mortality. In those patients who have pruritus
or cholangitis, the need for intervention is obvious, but
in those who have asymptomatic hyperbilirubinaemia
the indications are less clear. In a recent prospective
trial [12] using endoscopic stenting for inoperable
extrahepatic malignant jaundice, there was an
improvement in quality of life scores following biliary
decompression, but this was limited to those with a
bilirubin of 5250 mmol/l. Further data are therefore
required before definitive recommendations can be
made regarding this issue.
To relieve hyperbilirubinaemia and associated
pruritus, it is known that 30–50% of functioning liver
needs to be drained [13]. This equates to draining at
least segments III and IV and ideally II, III and IV for
a left-sided approach and at least two segments if a
right-sided approach is being considered. Equally,
draining a non-functioning atrophic lobe will not
be useful and may well compromise the patient by
introducing sepsis. For this reason knowledge of the
intrahepatic ductal anatomy is required. If drainage
is required for symptomatic cholangitis, draining one
lobe in the presence of an isolated infected contra-
lateral lobe will be unsuccessful and bilateral biliary
decompression should therefore be undertaken.
As with attempted resection, an overall assessment of
the patient’s preoperative function and ability to
withstand surgical intervention needs to be taken into
consideration.
Anatomical considerations
Surgical palliation for hilar cholangiocarcinoma can
involve anastomoses to the extrahepatic or selected
intrahepatic segmental ducts (mainly segment III).
The left hepatic duct is extrahepatic in its course and is
contained within a peritoneal extension that includes
the left portal vein and hepatic artery [14]. This portal
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triad lies under the base of segment IV covered by
fusion of Glisson’s capsule and peritoneum. The length
of the left hepatic duct is proportional to the length of
the base of segment IV [14]. It has a mean length
of 1.3 cm [15], but in 17% of cases it is56 mm [16],
making it susceptible to tumour involvement in the
presence of a hilar lesion. In this transverse segment
it is always superior to the portal vein and if there is
late union of the left hepatic duct, the segment II duct
tends to lie posterosuperiorly and the segment III/IV
duct anterosuperiorly before uniting just before the
hilum [17]. Having traversed the base of segment
IV the triad of structures reaches the umbilical fissure
where vessels divide into segmental branches II, III
and IV, with the equivalent segmental duct tributaries
converging to form the left hepatic duct. The com-
monest of the described variations occurs in 78–85%
of cases when segments II and III join in the umbilical
sulcus and segment IV drains at a variable point
between this and the confluence of the left and right
hepatic ducts [16,17]. In 10–15% of cases the left
hepatic duct is duplicated whereby segment III and
IV join initially and then converge with segment II at
a variable point before the main confluence [16,17].
In this situation if the origin of the left hepatic duct
is compromised by tumour, the segments may be
isolated rendering surgical drainage of segment III
ineffective.
The ligmentum teres enters the umbilical fissure to
attach to the lower (64%), middle (15%), or upper
(2%) aspect of the junction of the left portal vein as it
divides into its segmental branches [15]. It may be
bridged by a band of liver tissue which joins segments
III and IV. This does not contain any significant
structures but may be a guide to underlying aberrant
anatomy such as an infra-portal segment III bile duct
[18]. Classically the bile ducts are related intimately
to the umbilical plate [16] and are the first structures
encountered with an anterior approach to the liga-
mentum. An infra-portal segment III duct (6%) can
often be detected by preoperative imaging [18]. The
segment III duct is formed from an anteroinferior
and posterosuperior duct. The main segment III
duct runs adjacent to the left border of ligamentum
teres [16] into the umbilical sulcus where it joins
with the segment II duct. Thus segment III can easily
be exposed by dividing liver tissue to the left of
the ligamentum teres; however, if there has been
significant hypertrophy of the left lobe in response to
right-sided atrophy, the distance required to expose
the segment III ducts may be increased [16].
In contrast, the extrahepatic course of the right
hepatic duct is much shorter, and because of its
close proximity to the tumour does not allow
suitable access for surgical bypass. There are no
equivalent anatomical guides (ligamentum teres) to
the right-sided intrahepatic segmental ducts and
intraoperative ultrasound is required to identify
dilated segment V or VI ducts [16]. If this approach
is to be used knowledge of the right-sided sectoral
anatomy is important, as a segmental drainage
procedure will drain the whole right lobe effectively
in only 57% of cases [16].
Surgical techniques
Initial techniques described the placement of intra-
operative stents, or resectional-based intrahepatic
cholangioenterostomy; however, these have been
superseded by non-resectional hepatico- or cholangio-
jejunostomy [19]. This forms the basis of the technique
described below. Access is established through a
left/bilateral subcostal incision. The duodenum and
right colon are retracted inferiorly to expose the
porta hepatis. The falciform ligament is divided from
the anterior abdominal wall back to the point of the
triangular ligaments. Division and retraction of the
ligamentum teres on a secured ligature facilitates
exposure. Intraoperative assessment of the liver is
important, as the detection of significant metastatic
disease within the left lobe is a contraindication to left-
sided drainage.
Left hepatico-jejunostomy Roux-en-Y
Segment IV is retracted cranially to expose the area of
the confluence at the base of segment IV. If a bridge of
tissue lies across the ligamentum teres joining segment
III and IV, this can be divided to improve exposure to
the left hepatic duct [14]. To gain access to the left
hepatic duct, a plane between Glisson’s capsule and
the peritoneal extension encasing the portal triad
at the base of segment IV requires division. Deepening
the dissection will allow the left portal structures to
be lowered from the base of segment IV, whereas
extension to the right will allow access to the
confluence. In the presence of a Bismuth IIIa-IV lesion
or a large Bismuth I-II tumour [19] this may not be
possible since the tumour may be close to the proposed
anastomosis, thereby raising concerns about tumour
overgrowth. In this setting it is better to perform an
intrahepatic cholangio-jejunostomy.
If the left duct is deemed suitable, it is incised
longitudinally for the length of the exposed duct.
A retrocolic Roux limb is fashioned from proximal
jejunum. A side-to-side single layer interrupted muco-
sal to mucosal anastomosis is performed using a 4.0
monofilament suture. It may be useful to place two
stay sutures at either end of the anastomosis. In
placing the anterior row of sutures into the bile duct
(leaving the needles attached) as described by Voyles
and Blumgart [20], the anterior wall can be elevated to
facilitate accurate placement of the posterior sutures.
With all the posterior sutures in place the jejunum can
be parachuted down to approximate with the bile duct
and the sutures tied. In this way, the anterior row can
be completed under direct vision.
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Segment III cholangio-jejunostomy Roux-en-Y
In the event that the left duct is not suitable for
drainage an intrahepatic cholangio-jejunostomy, most
commonly to segment III, can be performed. The
ligamentum teres is retracted caudally and to the
patient’s right to expose the left border of segment
III, which is retracted with segment IV cranially.
The superior extensions of the ligamentum teres
and the liver tissue adjacent to its left are divided to
expose the umbilical plate that contains the segment
III duct. The depth of liver tissue which needs to be
opened will vary depending on the degree of left
lobe hypertrophy but the Cavitron Ultrasonic Surgical
Aspirator is ideal for undertaking a ‘bloodless’ dissec-
tion. The split needs to provide sufficient exposure
to allow the Roux limb to sit comfortably without
creating tension on the anastomosis [16]. We fre-
quently extend the incision to ‘saucerize’ the liver
overlying the segment III duct and this facilitates
construction of a larger enteric anastomosis while
minimizing kinking of the Roux-en-Y loop [21]. Small
vessels are encountered and can be controlled by
diathermy or ligation but it is rarely necessary to
control the hepatic inflow. With the duct exposed
for a 1–2 cm length, an anastomosis is performed
without a biliary stent using a similar technique to
that described above. It may be necessary to use an
end-to-side anastomosis so that the jejunum sits more
comfortably within the recess [22].
Right-sided hepatico-jejunostomy Roux-en-Y
For those patients in whom segment III cholangio-
jejunostomy is not feasible the remaining options
include radiological stenting, right segmental drainage
or intraoperative stent placement. Right-sided drain-
age requires identification of either the right anterior
sectoral or segmental ducts (V or VI), which are
exposed by a hepatotomy at the base of the gall bladder
fossa. The overlying liver parenchyma is divided to
expose the anterior sectoral duct longitudinally.
In many patients with malignant hilar disease, this
will not be easily achieved and intraoperative ultra-
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Figure 1. Algorithm for management of hilar cholangiocarcinoma. *Patients defined as high risk by Weber et al. [24].
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of the main segmental anatomy [16]. In those who
require bilateral drainage, palliation can be achieved
by performing a partial resection of the anterior part
of segment IV to expose the ducts draining segment
IV and V followed by separate cholangio-enteric
anastomoses [23]. All such approaches are more
demanding than those to the left side of the liver.
Who should have surgical palliation?
The options for palliation (Figure 1) can be divided
into non-operative or surgical bypass. Non-operative
biliary decompression (percutaneous transhepatic,
endoscopic or combined) can achieve satisfactory
short-term results [10,11]. Given the reported high
initial success rate and relatively low mortality asso-
ciated with radiological stenting, it would seem the
appropriate first-line approach to those with a life
expectancy of 56 months [24] and those unfit for
major surgical intervention.
Those patients with locally advanced disease
may have a better prognosis [8,24] and may be better
served by surgical palliation. Several surgical series
show that palliative bypass can be performed with
peri-operative mortality and morbidity rates varying
between 0–17% and 13–61%, respectively [6–8,
16,23,26–28]. Relief of jaundice can be obtained
in 67–100% [7,8,16,23,26] of patients undergoing
bypass, results which are comparable to those achieved
with radiological stenting [10,11]. Long-term morbid-
ity requiring further intervention is reported in 16–44%
of patients [7,8,16,25,26,28].
In our own institution, 201 patients with hilar
cholangiocarcinoma were assessed between December
1988 and March 2002 (unpublished data). Thirty-nine
(19.4%) underwent resection, 33 (16.4%) surgical
bypass, 125 (62.2%) underwent non-operative pallia-
tion and in 4 (2%) cases no treatment was offered.
The median survival rates (95% confidence intervals)
were 20 (12–28), 15 (5–25), 4 (3–5) months, res-
pectively. Comparison of patients who underwent
surgical palliation to those having non-operative
palliation showed that a younger cohort underwent
surgical intervention, but 30-day mortality and read-
mission rates were similar (Table I).
Several studies have compared survival times for
those palliated surgically or treated non-operatively.
There are conflicting data within the literature
[4,6,25,29] but these studies are non-randomized and
the heterogeneity of both patient and tumour factors
within and between studies makes any conclusions
invalid. Nonetheless, in a study reported by Traynor
and colleagues [22], 48 patients were managed over a
25-year period by segment III cholangio-jejunostomy
with low morbidity and mortality. Complete or partial
relief of jaundice was obtained in 73% and 23% of
patients, respectively. Mean duration of survival was
9.2 months and few patients experienced recurrent
jaundice or cholangitis [22].
The detection of distant nodal disease at the time of
attempted resection raises the issue of whether these
patients should undergo cholangio-jejunostomy or an
extrahepatic bile duct excision. It has been reported
that extrahepatic bile duct excision can be performed
with similar morbidity and mortality rates as reported
for surgical bypass [3] and offers excellent palliation
[30], with the advantage of draining both lobes. Whilst
a more radical approach may be considered, there is a
propensity for local recurrence [31], thereby rendering
such an anastomosis at increased risk of tumour
overgrowth compared with a segment III cholangio-
jejunostomy.
In conclusion, the majority of patients who are
diagnosed with hilar cholangiocarcinoma will require
a palliative approach. In those with a predicted
life expectancy of 56 months non-operative stenting
is the preferred treatment, but those with locally
advanced disease are likely to achieve better quality
palliation with surgical intervention, which can be
performed with similar morbidity and mortality to non-
operative techniques. There is a need for randomized
controlled data to identify the optimal approach
for the various subgroups of patients, particularly with
the improvements in endoscopic and radiological
prostheses. Such trials must include quality of life
assessment since this is ignored frequently in reported
series.
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